Under the agreement, as per the exchange filing, TheraNym will establish a large-scale mammalian cell culture-based facility with a total bioreactor capacity of 60,000 litres, along with the required downstream purification infrastructure to produce drug substances.
Also Read: Closing bell | Markets surge to near day’s high; Sensex jumps 1,264 points, ₹10 lakh crore added to investor wealth
TheraNym will undertake manufacturing at the facility and supply the products to MSD as per the terms of the arrangement. The company plans to invest around $150–175 million in setting up the facility.In its Q3 FY26 results, the firm had posted a net profit of ₹909.8 crore, up 7.5% year-on-year from ₹846 crore, inclusive of a one-time cost of ₹65 crore due to a change in the labour code.
Its revenue for the quarter grew 8.4% year-on-year to ₹8,646 crore, compared with ₹7,979 crore in the same period last year, supported by growth in Europe and the ARV (Antiretroviral drugs) segment.
Shares of Aurobindo Pharma Ltd ended higher on April 15, with the stock settling at ₹1,375.00 on the NSE, up ₹35.20 or 2.63% for the day. The stock has gained 24% over the past six months.
Also Read: Retail flows stay resilient as MF AUM falls 10.1% MoM in March: Motilal Oswal
